COMMUNIQUÉS West-GlobeNewswire

Alvotech Announces Increase in Number of Own Shares
22/03/2024
Alvotech (NASDAQ: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has increased the Company´s share capital by an amount of [...]
Alvotech Announces Increase in Number of Own Shares
22/03/2024
REYKJAVIK, Iceland, March 22, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, [...]
Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
22/03/2024
Patient Enrollment Resumed in the Investigator-initiated Phase 1/2 Clinical Trial of Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Company Implemented Significant Expense-reduction Measures [...]
Veru Reschedules Annual Meeting of Shareholders
22/03/2024
--Restated historical financial statements expected to be filed no later than April 15, 2024-- --2024 Annual Meeting of Shareholders to follow financial statements filings-- MIAMI, FL, March 22, 2024 (GLOBE NEWSWIRE [...]
Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results
22/03/2024
Daix (France), Long Island City (New York, United States), March 22, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule [...]
Inventiva annonce la date de publication et de présentation de ses résultats financiers 2023
22/03/2024
Daix (France), Long Island City (New York, Etats-Unis) , le 22 mars 2024 – Inventiva (Euronext Paris et Nasdaq : IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement clinique de petites [...]
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
22/03/2024
NOVATO, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare [...]
Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial
22/03/2024
Analysis of secondary endpoint of symptomatic COVID-19 events in CANOPY is unrelated to regulatory filing or review, but may be hypothesis generating for future Invivyd discovery and development work Today’s update on [...]
TFF Pharmaceuticals Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
22/03/2024
FORT WORTH, Texas, March 22, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage biopharmaceutical company focused on developing and [...]
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
22/03/2024
PEMGARDA (pemivibart) is authorized in the U.S. for PrEP of COVID-19 in certain adults and adolescents with moderate-to-severe immune compromise Emergency use authorization based on positive immunobridging data and on [...]
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
22/03/2024
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – March 22, 2024 – 07:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, [...]
Nextech Demos Patient Journey Innovations with Artificial Intelligence for Specialty Practices
22/03/2024
LAS VEGAS, March 22, 2024 (GLOBE NEWSWIRE) -- Nextech, market-leader of comprehensive technology solutions for specialty physician practices, today unveiled multiple transformative artificial intelligence solutions in [...]
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
22/03/2024
HOUSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of [...]
Join Lytus Technologies’ Exclusive Live Investor Webinar and Q&A Session on March 27
22/03/2024
Dubai, UAE, March 22, 2024 (GLOBE NEWSWIRE) -- Lytus Technologies Holdings PTV. Ltd. (the “Company”) (Nasdaq:LYT), a leading global technology-driven services company, is pleased to invite investors to a webinar on [...]
Theratechnologies Announces Update on its Preclinical Oncology Research Program
22/03/2024
Company continues to shift to commercial focus as it seeks partners to advance R&D MONTREAL, March 22, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX [...]
Theratechnologies fait le point sur son programme de recherche préclinique en oncologie
22/03/2024
La Société continue d’orienter ses efforts sur la commercialisation alors qu’elle cherche des partenaires pour faire progresser la R-D MONTRÉAL, 22 mars 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« [...]
Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response
22/03/2024
BEDMINSTER, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid [...]
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
22/03/2024
OCALA, Fla., March 22, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website. For the CEO [...]
Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
22/03/2024
WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the [...]

Pages